The Medtronic Newsroom is designed to assist media in finding news and information about our company.
Medtronic, founded in a Minneapolis garage in 1949 by Earl Bakken and his brother-in-law, Palmer Hermundslie, is the world’s leading maker of medical devices.
Our Mission has not changed since Earl Bakken wrote it in 1960: To contribute to human welfare by application of biomedical engineering in the research, design, manufacture, and sale of instruments or appliances that alleviate pain, restore health and extend life.
More than 9 million lives are enhanced every year by a Medtronic product or therapy; that’s one every three seconds.
Medtronic is headquartered in Minneapolis, MN and operates in more than 140 countries. The company employs 49,000 people, including 5,800 scientists and engineers, pursuing research and innovation that has led to more than 28,000 patents.
|11/18/14||Medtronic Reports Second Quarter Earnings|
|Revenue of $4.4 Billion Grew 5% on Constant Currency Basis; 4% as Reported
Non-GAAP Diluted EPS of $0.96, Growth of 5%; GAAP Diluted EPS of $0.83, Decline of 7%
Company Updates FY15 Revenue Growth Outlook; Reiterates FY15 EPS Guidance
Company Reaffirms Commitment to Covidien Transaction
MINNEAPOLIS - Nov. 18, 2014 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its second quarter of fiscal year 2015, which ended October 24, 2014.
The company reported worldwide seco... |
|11/17/14||Medtronic and Covidien Shareholder Meetings Scheduled for January 6, 2015|
|MINNEAPOLIS AND DUBLIN - Nov. 17, 2014 - Medtronic, Inc. (NYSE: MDT) and Covidien plc (NYSE: COV) announced that following a hearing today before the Irish High Court the companies have scheduled shareholder meetings for Tuesday, January 6, 2015, in connection with the pending acquisition of Covidien by Medtronic. Medtronic's special shareholder meeting will be held on January 6, 2015 at 8:00 a.m. local time at the Hyatt Regency, 1300 Nicollet Mall, Minneapolis, MN, 55403. This meeting is bei... |
|11/16/14||Medtronic Studies Show Cardiac Resynchronization Therapy Extends Life, Reduces Hospital Readmissions|
|Data Demonstrate Clinical and Economic Value of Underutilized Treatment for Heart Failure Patients at American Heart Association's Scientific Sessions 2014 MINNEAPOLIS and CHICAGO - Nov. 16, 2014 - Medtronic, Inc. (NYSE: MDT) today announced new data supporting the clinical and economic value of its cardiac resynchronization therapy (CRT) devices for the treatment of heart failure, including a significant reduction in all-cause 30-day readmissions after heart failure hospitalizations. Additiona... |
|Receive E-mail Alerts |
|Sign up to receive e-mail alerts whenever Medtronic posts new information to the site. Just enter your e-mail address and click Submit.|